Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.

Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The company said it has decided to price its version of Risdiplam product at Rs 15,900, and further added that it intends to ...

Natco Pharma on Tuesday shared a legal update on the legal proceedings on the Risdiplam compound (used for treating spinal ...

Telangana: Natco Pharma has announced the superannuation of Dr Ramesh Dandala, Executive Vice President - Technology Transfer ...

Indian pharma stocks surge as generic drugmakers exempted from U.S. tariff, boosting Nifty Pharma shares and industry outlook ...

Natco Pharma has announced the supperannuation of Tummala Venkata Rao, Vice President - Production of the Company."With ...

Currently, US charges nearly zero duty on pharmaceutical imports, while India imposes around 10 percent tax on pharma imports ...

Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...

In what could be promising news for patients battling spinal muscular atrophy (SMA), the Delhi High Court has refused to allow a suit by Swiss pharma giant Roche seeking to restrain Indian drugmaker ...

Dr. K.V. Swarajyalakshmi, the District Medical and Health Officer (DMHO), launched a program on Wednesday at the Collapur ...

Indian generics makers Cipla Ltd., Dr Reddy’s Laboratories Ltd, Lupin Ltd, Natco Pharma Ltd, Mankind Pharma Ltd, and Biocon Ltd are gearing up to launch copies of semaglutide in the market.